These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 11094308)

  • 1. Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain.
    González-Larriba JL; Serrano S; Alvarez-Mon M; Camacho F; Casado MA; Díaz-Pérez JL; Díaz-Rubio E; Fosbrook L; Guillem V; López-López JJ; Moreno-Nogueira JA; Toribio J
    Eur J Cancer; 2000 Dec; 36(18):2344-52. PubMed ID: 11094308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma.
    Hillner BE
    Eur J Cancer; 1998 Jul; 34 Suppl 3():S18-21. PubMed ID: 9849404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma.
    Messori A; Becagli P; Trippoli S; Tendi E
    Eur J Cancer; 1997 Aug; 33(9):1373-9. PubMed ID: 9337677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684.
    Hillner BE; Kirkwood JM; Atkins MB; Johnson ER; Smith TJ
    J Clin Oncol; 1997 Jun; 15(6):2351-8. PubMed ID: 9196150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma: a review.
    Crott R
    Pharmacoeconomics; 2004; 22(9):569-80. PubMed ID: 15209526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec.
    Crott R; Ali F; Burdette-Radoux S
    Value Health; 2004; 7(4):423-32. PubMed ID: 15449634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling the cost-effectiveness of sentinel lymph node mapping and adjuvant interferon treatment for stage II melanoma.
    Wilson LS; Reyes CM; Lu C; Lu M; Yen C
    Melanoma Res; 2002 Dec; 12(6):607-17. PubMed ID: 12459651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic analysis of adjuvant therapy with interferon alpha-2a in stage II malignant melanoma.
    Lafuma A; Dreno B; Delaunay M; Emery C; Fagnani F; Hieke K; Bonerandi JJ; Grob JJ;
    Eur J Cancer; 2001 Feb; 37(3):369-75. PubMed ID: 11239759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
    Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
    Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study.
    Cole BF; Gelber RD; Kirkwood JM; Goldhirsch A; Barylak E; Borden E
    J Clin Oncol; 1996 Oct; 14(10):2666-73. PubMed ID: 8874325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient preferences for adjuvant interferon alfa-2b treatment.
    Kilbridge KL; Weeks JC; Sober AJ; Haluska FG; Slingluff CL; Atkins MB; Sock DE; Kirkwood JM; Nease RF
    J Clin Oncol; 2001 Feb; 19(3):812-23. PubMed ID: 11157035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
    Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H;
    Lancet Oncol; 2011 Feb; 12(2):144-52. PubMed ID: 21256809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the role of adjuvant interferon for high risk melanoma.
    Agarwala SS; Kirkwood JM
    Forum (Genova); 2000; 10(3):230-9. PubMed ID: 11007931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on adjuvant interferon therapy for high-risk melanoma.
    Agarwala SS; Kirkwood JM
    Oncology (Williston Park); 2002 Sep; 16(9):1177-87; discussion 1190-2, 1197. PubMed ID: 12380946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
    Kirkwood JM; Strawderman MH; Ernstoff MS; Smith TJ; Borden EC; Blum RH
    J Clin Oncol; 1996 Jan; 14(1):7-17. PubMed ID: 8558223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial.
    Dixon S; Walters SJ; Turner L; Hancock BW
    Br J Cancer; 2006 Feb; 94(4):492-8. PubMed ID: 16449995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment.
    Ascierto PA; Napolitano M; Celentano E; Simeone E; Gentilcore G; Daponte A; Capone M; Caracò C; Calemma R; Beneduce G; Cerrone M; De Rosa V; Palmieri G; Castello G; Kirkwood JM; Marincola FM; Mozzillo N
    J Transl Med; 2010 Aug; 8():76. PubMed ID: 20712892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.
    Kirkwood JM; Manola J; Ibrahim J; Sondak V; Ernstoff MS; Rao U;
    Clin Cancer Res; 2004 Mar; 10(5):1670-7. PubMed ID: 15014018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.
    Bottomley A; Coens C; Suciu S; Santinami M; Kruit W; Testori A; Marsden J; Punt C; Salès F; Gore M; Mackie R; Kusic Z; Dummer R; Patel P; Schadendorf D; Spatz A; Keilholz U; Eggermont A
    J Clin Oncol; 2009 Jun; 27(18):2916-23. PubMed ID: 19433686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874].
    Chiarion-Sileni V; Del Bianco P; Romanini A; Guida M; Paccagnella A; Dalla Palma M; Naglieri E; Ridolfi R; Silvestri B; Michiara M; De Salvo GL
    BMC Cancer; 2006 Feb; 6():44. PubMed ID: 16504154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.